Leading the way to safer medication

Therapeutic Indications

Apremilast is indicated for:

Psoriasis, psoriatic arthritis

No gender/age discrimination

Apremilast, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.

Apremilast is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 10-60 mg in 2 divided doses daily

Contraindications

Active ingredient Apremilast is contraindicated in the following cases:

Pregnancy

No gender/age discrimination

There are limited data about the use of apremilast in pregnant women. Apremilast is contraindicated during pregnancy. Effects of apremilast on pregnancy included embryofetal loss in mice and monkeys, and reduced fetal weights and delayed ossification in mice at doses higher than the currently recommended highest human dose. No such effects were observed when exposure in animals was at 1.3-fold the clinical exposure.